H.R. 2374 · 116th Congress

Stop Significant and Time-wasting Abuse Limiting Legitimate Innovation of New Generics Act

Stage
Reported from committee
Sponsor
Hakeem Jeffries
Introduced
2019-04-29
Latest action
2020-12-24 · Reported by the Committee on Judiciary. H. Rept. 116-694.

Subjects

Administrative law and regulatory procedures
Health
Civil actions and liability
Licensing and registrations
Competition and antitrust
Public participation and lobbying
Business ethics
Drug safety, medical device, and laboratory regulation
Federal Trade Commission (FTC)